Edition:
United States

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

2.83USD
3:32pm EDT
Change (% chg)

$-0.07 (-2.41%)
Prev Close
$2.90
Open
$2.92
Day's High
$2.99
Day's Low
$2.81
Volume
304,619
Avg. Vol
694,524
52-wk High
$27.93
52-wk Low
$1.02

Latest Key Developments (Source: Significant Developments)

Patrick Machado Says Axovant Sciences Agreed To Sell To Roivant 14.3 Mln Shares
Thursday, 7 Jun 2018 07:54am EDT 

June 7 (Reuters) - Patrick Machado::PATRICK MACHADO SAYS ON JUNE 5, ROIVANT ENTERED SHARE PURCHASE AGREEMENT - SEC FILING.PATRICK MACHADO SAYS AXOVANT SCIENCES AGREED TO ISSUE, SELL TO ROIVANT 14.3 MILLION SHARES AT $1.75/ SHARE IN A PRIVATE PLACEMENT.PATRICK MACHADO SAYS ROIVANT PROVIDED FINANCING WITH AXOVANT'S ENTRY TO LICENSE AGREEMENT WITH OXFORD BIOMEDICA.PATRICK MACHADO - ROIVANT REMAINS DIRECT OWNER OF 89.3 MILLION SHARES OF AXOVANT, INCLUDING 75 MILLION SHARES BENEFICIALLY OWNED BEFORE AXOVANT’S IPO.PATRICK MACHADO SAYS SHARES DISPOSITIVE POWER OVER ROIVANT’S 89.3 MILLION SHARES OF AXOVANT WITH OTHER INDEPENDENT DIRECTOR OF ROIVANT CURRENTLY SERVING.  Full Article

Axovant Sciences Initiated Reduction In Its Workforce
Wednesday, 14 Feb 2018 06:07pm EST 

Feb 14 (Reuters) - Axovant Sciences Ltd ::AXOVANT SCIENCES LTD - ‍ ON FEBRUARY 12, INITIATED A CORPORATE REALIGNMENT THAT INCLUDED A REDUCTION IN ITS WORKFORCE - SEC FILING.AXOVANT SCIENCES - ‍EXPECTS TO COMPLETE REDUCTION IN HEADCOUNT, EMPLOYEE TRANSFERS, INCLUDING PAYMENT OF EMPLOYEE SEVERANCE, BENEFITS, IN Q3 2018​.AXOVANT SCIENCES LTD - EXPECTS REALIGNMENT ACTIONS TO RESULT IN RESTRUCTURING CHARGE OF ABOUT $1.5 MILLION FOR EMPLOYEE SEVERANCE AND RELATED COSTS​.AXOVANT SCIENCES LTD - ‍ EXPECTS REALIGNMENT ACTIONS, CHANGES IN MANAGEMENT TO RESULT IN ANNUALIZED COST SAVINGS OF BETWEEN ABOUT $6.0 MILLION AND $8.0 MILLION​.  Full Article

BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study
Wednesday, 6 Dec 2017 05:23pm EST 

Corrects headline to say the final protocol was submitted for dementia with Lewy bodies study, not Parkinson's study:AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT.AXOVANT SCIENCES LTD SAYS SUBMITTED PROTOCOL THAT DESIGNATES ADAS-COG & CIBIC+ AS CO-SECONDARY ENDPOINTS FOR PHASE 2B HEADWAY STUDY - SEC FILING.  Full Article

Axovant announces second fiscal quarter results
Thursday, 2 Nov 2017 04:30pm EDT 

Nov 2 (Reuters) - Axovant Sciences Ltd :Axovant announces second fiscal quarter financial results and corporate updates.Q2 loss per share $0.64.Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.Axovant Sciences Ltd - ‍Axovant held cash of $235.4 million at september 30, 2017​.  Full Article

Axovant announces negative topline results of intepirdine phase 3 mindset trial in Alzheimer's disease
Tuesday, 26 Sep 2017 07:00am EDT 

Sept 26 (Reuters) - Axovant Sciences Ltd :At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition.Axovant Sciences - ‍announced that phase 3 mindset clinical trial of its investigational drug intepirdine did not meet its co-primary efficacy endpoints​.Axovant Sciences Ltd - ‍in study, intepirdine was generally well tolerated​.Axovant Sciences - ‍headway trial studying intepirdine in patients with dementia remains on track to report topline results at end of 2017​.Axovant Sciences - ‍after 24 weeks of treatment, change from baseline in cognition was non-significantly improved in intepirdine arm versus placebo arm​.Axovant Sciences Ltd - ‍there was essentially no difference between intepirdine and placebo arms in change from baseline in activities of daily living​.Axovant Sciences - ‍headway trial studying intepirdine in patients with dementia with lewy bodies remains on track to report topline results at end of 2017​.Axovant Sciences - ‍only endpoint in which any significant improvement was seen in intepirdine arm versus placebo arm was in first key secondary endpoint​.Axovant Sciences Ltd - ‍company will work with investigators to conclude mindset open-label extension study​.  Full Article

Axovant to move stock exchange listing to Nasdaq
Monday, 21 Aug 2017 04:15pm EDT 

Aug 21 (Reuters) - Axovant Sciences Ltd :Axovant to move stock exchange listing to Nasdaq.Axovant Sciences Ltd says it will voluntarily move its stock exchange listing from New York Stock Exchange to Nasdaq Global Select Market.Axovant Sciences Ltd - ‍Move is expected to become effective on or about September 6, 2017​.Axovant Sciences Ltd - ‍Company's common shares will continue to trade under ticker symbol "AXON."​.  Full Article

Axovant Sciences reports Q1 loss per share of $0.65
Monday, 7 Aug 2017 07:00am EDT 

Aug 7 (Reuters) - Axovant Sciences Ltd :Axovant announces fiscal first quarter financial results and corporate updates.Q1 loss per share $0.65.Q1 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.  Full Article

Dermavant Sciences names Celgene's ex-COO Jacqualyn fouse executive chairman
Monday, 10 Jul 2017 08:45am EDT 

July 10 (Reuters) - Dermavant Sciences-:Dermavant Sciences appoints Dr. Jacqualyn Fouse as executive chairman.Dermavant Sciences - ‍fouse recently served as president and COO of Celgene Corp​.  Full Article

Axovant Sciences' Q4 loss per share $0.53
Tuesday, 13 Jun 2017 07:00am EDT 

June 13 (Reuters) - Axovant Sciences Ltd :Axovant Sciences announces fiscal year-end financial results and corporate updates.Q4 loss per share $0.53.Q4 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Expects to meet with U.S. Food and Drug Administration to discuss additional studies that could support registration of RVT-103.Axovant Sciences Ltd says expects to initiate a proof of concept study for RVT-104 in second half of 2017.  Full Article

Axovant Sciences announces pricing of $125 mln public offering of common shares
Tuesday, 11 Apr 2017 07:00am EDT 

Axovant Sciences Ltd : Axovant sciences ltd. Announces pricing of $125m public offering of common shares .Says public offering of 6.74 million common shares priced at $18.54per share.  Full Article

BRIEF-Axovant Sciences Initiated Reduction In Its Workforce

* AXOVANT SCIENCES LTD - ‍ ON FEBRUARY 12, INITIATED A CORPORATE REALIGNMENT THAT INCLUDED A REDUCTION IN ITS WORKFORCE - SEC FILING